21 results on '"Staflin K"'
Search Results
2. Activated tumor cell integrin alpha v beta 3 cooperates with platelets to promote extravasation and metastasis from the blood stream
- Author
-
Weber, MR, Zuka, M, Lorger, M, Tschan, M, Torbett, BE, Zijlstra, A, Quigley, JP, Staflin, K, Eliceiri, BP, Krueger, JS, Marchese, P, Ruggeri, ZM, and Felding, BH
- Subjects
Platelets ,Extravasation ,Integrin activation ,Blood stream ,Metastasis - Published
- 2016
3. Combretastatin A-1 phosphate potentiates the antitumor activity of carboplatin and paclitaxel in a severe combined immunodeficiency disease (SCID) mouse model of human ovarian carcinoma
- Author
-
STAFLIN, K., primary, JARNUM, S., additional, HUA, J., additional, HONETH, G., additional, KANNISTO, P., additional, and LINDVALL, M., additional
- Published
- 2006
- Full Text
- View/download PDF
4. Chemokine-directed migration of tumor-inhibitory neural progenitor cells towards an intracranially growing glioma
- Author
-
HONETH, G, primary, STAFLIN, K, additional, KALLIOMAKI, S, additional, LINDVALL, M, additional, and KJELLMAN, C, additional
- Published
- 2006
- Full Text
- View/download PDF
5. Identification of proteins involved in neural progenitor cell targeting of gliomas
- Author
-
Honeth Gabriella, Zuchner Thole, Staflin Karin, Darabi Anna, and Lundberg Cecilia
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Glioblastoma are highly aggressive tumors with an average survival time of 12 months with currently available treatment. We have previously shown that specific embryonic neural progenitor cells (NPC) have the potential to target glioma growth in the CNS of rats. The neural progenitor cell treatment can cure approximately 40% of the animals with malignant gliomas with no trace of a tumor burden 6 months after finishing the experiment. Furthermore, the NPCs have been shown to respond to signals from the tumor environment resulting in specific migration towards the tumor. Based on these results we wanted to investigate what factors could influence the growth and progression of gliomas in our rodent model. Methods Using microarrays we screened for candidate genes involved in the functional mechanism of tumor inhibition by comparing glioma cell lines to neural progenitor cells with or without anti-tumor activity. The expression of candidate genes was confirmed at RNA level by quantitative RT-PCR and at the protein level by Western blots and immunocytochemistry. Moreover, we have developed in vitro assays to mimic the antitumor effect seen in vivo. Results We identified several targets involved in glioma growth and migration, specifically CXCL1, CD81, TPT1, Gas6 and AXL proteins. We further showed that follistatin secretion from the NPC has the potential to decrease tumor proliferation. In vitro co-cultures of NPC and tumor cells resulted in the inhibition of tumor growth. The addition of antibodies against proteins selected by gene and protein expression analysis either increased or decreased the proliferation rate of the glioma cell lines in vitro. Conclusion These results suggest that these identified factors might be useful starting points for performing future experiments directed towards a potential therapy against malignant gliomas.
- Published
- 2009
- Full Text
- View/download PDF
6. Correction to: Preclinical development of ZED8, an 89 Zr immuno‑PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy.
- Author
-
Ogasawara A, Kiefer JR, Gill H, Chiang E, Sriraman S, Ferl GZ, Ziai J, Bohorquez SS, Guelman S, Wang X, Yang J, Phan MM, Nguyen V, Chung S, Yu C, Tinianow J, Waaijer SJH, De Crespigny A, Marik J, Boswell CA, Zabka T, Staflin K, and Williams SP
- Published
- 2023
- Full Text
- View/download PDF
7. Preclinical development of ZED8, an 89 Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy.
- Author
-
Ogasawara A, Kiefer JR, Gill H, Chiang E, Sriraman S, Ferl GZ, Ziai J, Bohorquez SS, Guelman S, Wang X, Yang J, Phan MM, Nguyen V, Chung S, Yu C, Tinianow J, Waaijer SJH, De Crespigny A, Marik J, Boswell CA, Zabka T, Staflin K, and Williams SP
- Subjects
- Adult, Humans, Mice, Rats, Animals, Indicators and Reagents therapeutic use, Tissue Distribution, Immunotherapy methods, Zirconium chemistry, CD8-Positive T-Lymphocytes metabolism, Cell Line, Tumor, Positron-Emission Tomography methods, Neoplasms therapy, Neoplasms drug therapy
- Abstract
Background: ZED8 is a novel monovalent antibody labeled with zirconium-89 for the molecular imaging of CD8. This work describes nonclinical studies performed in part to provide rationale for and to inform expectations in the early clinical development of ZED8, such as in the studies outlined in clinical trial registry NCT04029181 [1]., Methods: Surface plasmon resonance, X-ray crystallography, and flow cytometry were used to characterize the ZED8-CD8 binding interaction, its specificity, and its impact on T cell function. Immuno-PET with ZED8 was assessed in huCD8
+ tumor-bearing mice and in non-human primates. Plasma antibody levels were measured by ELISA to determine pharmacokinetic parameters, and OLINDA 1.0 was used to estimate radiation dosimetry from image-derived biodistribution data., Results: ZED8 selectively binds to human CD8α at a binding site approximately 9 Å from that of MHCI making mutual interference unlikely. The equilibrium dissociation constant (KD ) is 5 nM. ZED8 binds to cynomolgus CD8 with reduced affinity (66 nM) but it has no measurable affinity for rat or mouse CD8. In a series of lymphoma xenografts, ZED8 imaging was able to identify different CD8 levels concordant with flow cytometry. In cynomolgus monkeys with tool compound89 Zr-aCD8v17, lymph nodes were conspicuous by imaging 24 h post-injection, and the pharmacokinetics suggested a flat-fixed first-in-human dose of 4 mg per subject. The whole-body effective dose for an adult human was estimated to be 0.48 mSv/MBq, comparable to existing89 Zr immuno-PET reagents., Conclusion:89 Zr immuno-PET with ZED8 appears to be a promising biomarker of tissue CD8 levels suitable for clinical evaluation in cancer patients eligible for immunotherapy., (© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)- Published
- 2023
- Full Text
- View/download PDF
8. Development of the first reference antibody panel for qualification and validation of cytokine release assay platforms - Report of an international collaborative study.
- Author
-
Vessillier S, Fort M, O'Donnell L, Hinton H, Nadwodny K, Piccotti J, Rigsby P, Staflin K, Stebbings R, Mekala D, Willingham A, and Wolf B
- Abstract
Immunomodulatory therapeutics such as monoclonal antibodies (mAb) carry an inherent risk of undesired immune reactions. One such risk is cytokine release syndrome (CRS), a rapid systemic inflammatory response characterized by the secretion of pro-inflammatory cytokines from immune cells. It is crucial for patient safety to correctly identify potential risk of CRS prior to first-in-human dose administration. For this purpose, a variety of in vitro cytokine release assays (CRA) are routinely used as part of the preclinical safety assessment of novel therapeutic mAbs. One of the challenges for the development and comparison of CRA performance is the lack of availability of standard positive and negative control mAbs for use in assay qualification. To address this issue, the National Institute for Biological Standards and Control (NIBSC) developed a reference panel of lyophilised mAbs known to induce CRS in the clinic: human anti-CD52, mouse anti-CD3 and human superagonistic (SA) anti-CD28 mAb manufactured according to the respective published sequences of Campath-1H® (alemtuzumab, IgG1) , Orthoclone OKT-3® (muromonab, IgG2a) and TGN1412 (theralizumab, IgG4), as well as three isotype matched negative controls (human IgG1, mouse IgG2a and human IgG4, respectively). The relative capacity of these control mAbs to stimulate the release of IFN-γ, IL-2, TNF-α and IL-6 in vitro was evaluated in eleven laboratories in an international collaborative study mediated through the HESI Immuno-safety Technical Committee Cytokine Release Assay Working Group. Participants tested the NIBSC mAbs in a variety of CRA platforms established at each institution. This paper presents the results from the centralised cytokine quantification on all the plasma/supernatants corresponding to the stimulation of immune cells in the different CRA platforms by a single concentration of each mAb. Each positive control mAb induced significant cytokine release in most of the tested CRA platforms. There was a high inter-laboratory variability in the levels of cytokines produced, but similar patterns of response were observed across laboratories that replicated the cytokine release patterns previously published for the respective clinical therapeutic mAbs. Therefore, the positive and negative mAbs are suitable as a reference panel for the qualification and validation of CRAs, comparison of different CRA platforms (e.g. solid vs aqueous phase), and intra- and inter-laboratory comparison of CRA performance. Thus, the use of this panel of positive and negative control mAbs will increase the confidence in the robustness of a CRA platform to identify a potential CRS risk for novel immunomodulatory therapeutic candidates., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Crown Copyright © 2020 Published by Elsevier Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
9. Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody.
- Author
-
Staflin K, Zuch de Zafra CL, Schutt LK, Clark V, Zhong F, Hristopoulos M, Clark R, Li J, Mathieu M, Chen X, Johnston J, Low J, Ybarra R, Slaga D, Yang J, Ovacik M, Dybdal NO, Totpal K, Junttila MR, Ellerman D, Lee G, Dennis MS, Prell R, and Junttila TT
- Subjects
- Animals, Antibodies, Bispecific chemistry, Antineoplastic Agents, Immunological chemistry, CD3 Complex chemistry, CHO Cells, Cricetulus, Drug Evaluation, Preclinical, Humans, Macaca fascicularis, Receptor, ErbB-2 chemistry, Antibodies, Bispecific immunology, Antibody Affinity, Antineoplastic Agents, Immunological immunology, Receptor, ErbB-2 immunology
- Abstract
Systemic cytokine release and on-target/off-tumor toxicity to normal tissues are the main adverse effects limiting the clinical utility of T cell-redirecting therapies. This study was designed to determine how binding affinity for CD3 and tumor target HER2 impact the efficacy and nonclinical safety of anti-HER2/CD3 T cell-dependent antibodies (TDBs). Affinity was found to be a major determinant for the overall tolerability. Higher affinity for CD3 associated with rapidly elevated peripheral cytokine concentrations, weight loss in mice, and poor tolerability in cynomolgus monkeys. A TDB with lower CD3 affinity was better tolerated in cynomolgus monkeys compared with a higher CD3-affinity TDB. In contrast to tolerability, T cell binding affinity had only limited impact on in vitro and in vivo antitumor activity. High affinity for HER2 was critical for the tumor-killing activity of anti-HER2/CD3 TDBs, but higher HER2 affinity also associated with a more severe toxicity profile, including cytokine release and damage to HER2-expressing tissues. The tolerability of the anti-HER2/CD3 was improved by implementing a dose-fractionation strategy. Fine-tuning the affinities for both the tumor target and CD3 is likely a valuable strategy for achieving maximal therapeutic index of CD3 bispecific antibodies.
- Published
- 2020
- Full Text
- View/download PDF
10. In vitro assessment of chemotherapy-induced neuronal toxicity.
- Author
-
Snyder C, Yu L, Ngo T, Sheinson D, Zhu Y, Tseng M, Misner D, and Staflin K
- Subjects
- Apoptosis drug effects, Cells, Cultured, Gene Expression drug effects, Humans, Neurites drug effects, Neurons metabolism, Neurotoxicity Syndromes, Antineoplastic Agents toxicity, Drug Evaluation, Preclinical methods, Induced Pluripotent Stem Cells cytology, Neurons drug effects
- Abstract
Neurotoxicity is a major concern during drug development, and together with liver and cardio-toxicity, it is one of the main causes of clinical drug attrition. Current pre-clinical models may not sufficiently identify and predict the risk for central or peripheral nervous system toxicity. One such example is clinically dose-limiting neuropathic effects after the administration of chemotherapeutic agents. Thus, the need to establish novel in vitro tools to evaluate the risk of neurotoxicities, such as neuropathy, remains unmet in drug discovery. Though in vitro studies have been conducted using primary and immortalized cell lines, some limitations include the utility for higher throughput methodologies, method reproducibility, and species extrapolation. As a novel alternative, human induced-pluripotent stem cell (iPSC)-derived neurons appear promising for testing new drug candidates. These iPSC-derived neurons are readily available and can be manipulated as required. Here, we describe a novel approach to assess neurotoxicity caused by different classes of chemotherapeutics using kinetic monitoring of neurite dynamic changes and apoptosis in human iPSC-neurons. These studies show promising changes in neurite dynamics in response to clinical inducers of neuropathy, as well as the ability to rank-order and gather mechanistic insight into class-specific compound induced neurotoxicity. This platform can be utilized in early drug development, as part of a weight of evidence approach, to screen drug candidates, and potentially reduce clinical attrition due to neurotoxicity., (Copyright © 2018 Elsevier Ltd. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
11. Evaluation of the Toxicity of Intravitreally Injected PLGA Microspheres and Rods in Monkeys and Rabbits: Effects of Depot Size on Inflammatory Response.
- Author
-
Thackaberry EA, Farman C, Zhong F, Lorget F, Staflin K, Cercillieux A, Miller PE, Schuetz C, Chang D, Famili A, Daugherty AL, Rajagopal K, and Bantseev V
- Subjects
- Animals, Biocompatible Materials administration & dosage, Cytokines metabolism, Disease Models, Animal, Foreign-Body Reaction metabolism, Foreign-Body Reaction pathology, Intravitreal Injections, Lactic Acid administration & dosage, Macrophages metabolism, Polyglycolic Acid administration & dosage, Polylactic Acid-Polyglycolic Acid Copolymer, Rabbits, Retina drug effects, Retina pathology, Vitreous Body drug effects, Vitreous Body pathology, Biocompatible Materials toxicity, Drug Delivery Systems adverse effects, Lactic Acid toxicity, Microspheres, Polyglycolic Acid toxicity
- Abstract
Purpose: Poly(lactic-co-glycolic) acid (PLGA) inserts have been successfully developed for the treatment of posterior eye disease as a means of reducing injection frequency of intravitreally administered therapeutics. PLGA microspheres are also of interest for the delivery of intravitreal drugs, since they offer the advantage of being easily injected without surgical procedures or large injectors., Methods: In the current study, the toxicity of PLGA microspheres and rods was investigated in nonhuman primates (NHPs) and rabbits. An in vitro assessment of cytokine responses to PLGA in peripheral blood mononuclear cells (PBMCs) and macrophages was also performed., Results: Intravitreal administration of 3, 10, or 12.5 mg/eye of PLGA microspheres in NHPs resulted in a severe immune response characterized by a foreign body response. Follow-up studies in the rabbit confirmed this finding for PLGA microspheres ranging in size from 20 to 100 μm. In contrast, administration of PLGA rod implants with a similar PLGA mass did not elicit a significant immune response. In vitro assays in PBMCs and macrophages confirmed proinflammatory cytokine release upon treatment with PLGA microspheres but not PLGA rods., Conclusions: These data demonstrate a lack of tolerability of PLGA microspheres upon intravitreal injection, and suggest that the size, shape, and/or surface area of PLGA depots are critical attributes in determining ocular toxicity.
- Published
- 2017
- Full Text
- View/download PDF
12. Bruton's Tyrosine Kinase Small Molecule Inhibitors Induce a Distinct Pancreatic Toxicity in Rats.
- Author
-
Erickson RI, Schutt LK, Tarrant JM, McDowell M, Liu L, Johnson AR, Lewin-Koh SC, Hedehus M, Ross J, Carano RA, Staflin K, Zhong F, Crawford JJ, Zhong S, Reif K, Katewa A, Wong H, Young WB, Dambach DM, and Misner DL
- Subjects
- Agammaglobulinaemia Tyrosine Kinase, Animals, Dogs, Dose-Response Relationship, Drug, Female, Gene Expression Regulation, Enzymologic drug effects, Glucose metabolism, Humans, Male, Mice, Pancreas metabolism, Protein-Tyrosine Kinases metabolism, Rats, Species Specificity, Pancreas drug effects, Piperazines toxicity, Protein Kinase Inhibitors toxicity, Protein-Tyrosine Kinases antagonists & inhibitors, Pyridones toxicity, Pyrroles toxicity
- Abstract
Bruton's tyrosine kinase (BTK) is a member of the Tec family of cytoplasmic tyrosine kinases involved in B-cell and myeloid cell signaling. Small molecule inhibitors of BTK are being investigated for treatment of several hematologic cancers and autoimmune diseases. GDC-0853 ((S)-2-(3'-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4'-bipyridin]-2'-yl)-7,7-dimethyl-3,4,7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one) is a selective and reversible oral small-molecule BTK inhibitor in development for the treatment of rheumatoid arthritis and systemic lupus erythematosus. In Sprague-Dawley (SD) rats, administration of GDC-0853 and other structurally diverse BTK inhibitors for 7 days or longer caused pancreatic lesions consisting of multifocal islet-centered hemorrhage, inflammation, fibrosis, and pigment-laden macrophages with adjacent lobular exocrine acinar cell atrophy, degeneration, and inflammation. Similar findings were not observed in mice or dogs at much higher exposures. Hemorrhage in the peri-islet vasculature emerged between four and seven daily doses of GDC-0853 and was histologically similar to spontaneously occurring changes in aging SD rats. This suggests that GDC-0853 could exacerbate a background finding in younger animals. Glucose homeostasis was dysregulated following a glucose challenge; however, this occurred only after 28 days of administration and was not directly associated with onset or severity of pancreatic lesions. There were no changes in other common serum biomarkers assessing endocrine and exocrine pancreatic function. Additionally, these lesions were not readily detectable via Doppler ultrasound, computed tomography, or magnetic resonance imaging. Our results indicate that pancreatic lesions in rats are likely a class effect of BTK inhibitors, which may exacerbate an islet-centered pathology that is unlikely to be relevant to humans., (Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.)
- Published
- 2017
- Full Text
- View/download PDF
13. Activated tumor cell integrin αvβ3 cooperates with platelets to promote extravasation and metastasis from the blood stream.
- Author
-
Weber MR, Zuka M, Lorger M, Tschan M, Torbett BE, Zijlstra A, Quigley JP, Staflin K, Eliceiri BP, Krueger JS, Marchese P, Ruggeri ZM, and Felding BH
- Subjects
- Animals, Blood Platelets metabolism, Cell Line, Tumor, Cell Movement, Humans, Integrin alphaVbeta3 analysis, Mice, SCID, Neoplastic Cells, Circulating metabolism, Blood Platelets pathology, Integrin alphaVbeta3 metabolism, Neoplasm Metastasis pathology, Neoplastic Cells, Circulating pathology
- Abstract
Metastasis is the main cause of death in cancer patients, and understanding mechanisms that control tumor cell dissemination may lead to improved therapy. Tumor cell adhesion receptors contribute to cancer spreading. We noted earlier that tumor cells can expressing the adhesion receptor integrin αvβ3 in distinct states of activation, and found that cells which metastasize from the blood stream express it in a constitutively high affinity form. Here, we analyzed steps of the metastatic cascade in vivo and asked, when and how the affinity state of integrin αvβ3 confers a critical advantage to cancer spreading. Following tumor cells by real time PCR, non-invasive bioluminescence imaging, intravital microscopy and histology allowed us to identify tumor cell extravasation from the blood stream as a rate-limiting step supported by high affinity αvβ3. Successful transendothelial migration depended on cooperation between tumor cells and platelets involving the high affinity tumor cell integrin and release of platelet granules. Thus, this study identifies the high affinity conformer of integrin αvβ3 and its interaction with platelets as critical for early steps during hematogenous metastasis and target for prevention of metastatic disease., (© 2016 Elsevier Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
14. Selective formation of covalent protein heterodimers with an unnatural amino acid.
- Author
-
Hutchins BM, Kazane SA, Staflin K, Forsyth JS, Felding-Habermann B, Smider VV, and Schultz PG
- Subjects
- Antibodies, Monoclonal genetics, Antibodies, Monoclonal metabolism, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Phytogenic immunology, Antineoplastic Agents, Phytogenic toxicity, Cell Line, Tumor, Dimerization, Humans, Immunoglobulin Fab Fragments chemistry, Immunoglobulin Fab Fragments genetics, Immunoglobulin Fab Fragments metabolism, Immunotoxins immunology, Immunotoxins toxicity, Maleimides chemistry, Phenylalanine chemistry, Receptor, ErbB-2 immunology, Recombinant Proteins chemistry, Recombinant Proteins genetics, Recombinant Proteins metabolism, Ribosome Inactivating Proteins, Type 1 genetics, Ribosome Inactivating Proteins, Type 1 metabolism, Saporins, Trastuzumab, Antibodies, Monoclonal chemistry, Antineoplastic Agents, Phytogenic chemistry, Immunotoxins chemistry, Phenylalanine analogs & derivatives, Ribosome Inactivating Proteins, Type 1 chemistry
- Abstract
We report a strategy for the generation of heterodimeric protein conjugates using an unnatural amino acid with orthogonal reactivity. This paper addresses the challenges of site-specificity and homogeneity with respect to the synthesis of bivalent proteins and antibody-drug conjugates. There are numerous antibody-drug conjugates in preclinical and clinical development, yet these are based either on nonspecific lysine coupling chemistry or on disulfide modification made difficult by the large number of cysteines in antibodies. Here, we describe a recombinant approach that can be used to rapidly generate a variety of constructs with defined conjugation sites. Moreover, this methodology results in homogeneous antibody conjugates whose biological, physical, and pharmacological properties can be quantitatively assessed and subsequently optimized. As proof of concept, we have generated anti-Her2 Fab-Saporin conjugates that demonstrate excellent potency in vitro., (Copyright © 2011 Elsevier Ltd. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
15. Site-specific coupling and sterically controlled formation of multimeric antibody fab fragments with unnatural amino acids.
- Author
-
Hutchins BM, Kazane SA, Staflin K, Forsyth JS, Felding-Habermann B, Schultz PG, and Smider VV
- Subjects
- Humans, Immunoglobulin Fab Fragments genetics, Kinetics, Models, Chemical, Models, Molecular, Phenylalanine metabolism, Protein Binding, Protein Structure, Quaternary, Receptor, ErbB-2 immunology, Amino Acids metabolism, Immunoglobulin Fab Fragments chemistry, Immunoglobulin Fab Fragments metabolism, Phenylalanine analogs & derivatives, Protein Multimerization
- Abstract
Immunoconjugates and multispecific antibodies are rapidly emerging as highly potent experimental therapeutics against cancer. We have developed a method to incorporate an unnatural amino acid, p-acetylphenylalanine (pAcPhe) into an antibody antigen binding fragment (Fab) targeting HER2 (human epidermal growth factor receptor 2), allowing site-specific labeling without disrupting antigen binding. Expression levels of the pAcPhe-containing proteins were comparable to that of wild-type protein in shake-flask and fermentation preparations. The pAcPhe-Fabs were labeled by reaction with hydroxylamine dye and biotin species to produce well-defined, singly conjugated Fabs. We then coupled a hydroxylamine biotin to the pAcPhe-Fab and demonstrated controlled assembly of Fabs in the presence of the tetrameric biotin-binding protein, NeutrAvidin. The position of Fab biotinylation dictates the geometry of multimer assembly, producing unique multimeric Fab structures. These assembled Fab multimers differentially attenuate Her2 phosphorylation in breast cancer cells that overexpress the Her2 receptor. Thus, an encoded unnatural amino acid produces a chemical "handle" by which immunoconjugates and multimers can be engineered., (Copyright © 2011. Published by Elsevier Ltd.)
- Published
- 2011
- Full Text
- View/download PDF
16. Targeting activated integrin alphavbeta3 with patient-derived antibodies impacts late-stage multiorgan metastasis.
- Author
-
Staflin K, Krueger JS, Hachmann J, Forsyth JS, Lorger M, Steiniger SC, Mee J, Pop C, Salvesen GS, Janda KD, and Felding-Habermann B
- Subjects
- Animals, Caspase 3 metabolism, Disease Models, Animal, Humans, Integrin alphaVbeta3 immunology, Integrin alphaVbeta3 metabolism, Mice, Mice, SCID, Neoplasm Metastasis immunology, Neoplasm Metastasis prevention & control, Single-Chain Antibodies immunology, Integrin alphaVbeta3 antagonists & inhibitors, Neoplasm Metastasis drug therapy, Neoplasm Metastasis pathology, Single-Chain Antibodies therapeutic use
- Abstract
Advanced metastatic disease is difficult to manage and specific therapeutic targets are rare. We showed earlier that metastatic breast cancer cells use the activated conformer of adhesion receptor integrin alphavbeta3 for dissemination. We now investigated if targeting this form of the receptor can impact advanced metastatic disease, and we analyzed the mechanisms involved. Treatment of advanced multi-organ metastasis in SCID mice with patient-derived scFv antibodies specific for activated integrin alphavbeta3 caused stagnation and regression of metastatic growth. The antibodies specifically localized to tumor lesions in vivo and inhibited alphavbeta3 ligand binding at nanomolar levels in vitro. At the cellular level, the scFs associated rapidly with high affinity alphavbeta3 and dissociated extremely slowly. Thus, the scFvs occupy the receptor on metastatic tumor cells for prolonged periods of time, allowing for inhibition of established cell interaction with natural alphavbeta3 ligands. Potential apoptosis inducing effects of the antibodies through interaction with caspase-3 were studied as potential additional mechanism of treatment response. However, in contrast to a previous concept, neither the RGD-containing ligand mimetic scFvs nor RGD peptides bound or activated caspase-3 at the cellular or molecular level. This indicates that the treatment effects seen in the animal model are primarily due to antibody interference with alphavbeta3 ligation. Inhibition of advanced metastatic disease by treatment with cancer patient derived single chain antibodies against the activated conformer of integrin alphavbeta3 identifies this form of the receptor as a suitable target for therapy.
- Published
- 2010
- Full Text
- View/download PDF
17. Absence of striatal newborn neurons with mature phenotype following defined striatal and cortical excitotoxic brain injuries.
- Author
-
Deierborg T, Staflin K, Pesic J, Roybon L, Brundin P, and Lundberg C
- Subjects
- Animals, Biomarkers, Brain Injury, Chronic chemically induced, Bromodeoxyuridine, Cell Differentiation physiology, Cell Movement physiology, Cell Proliferation, Cerebral Cortex drug effects, Cerebral Cortex physiopathology, Corpus Striatum cytology, Corpus Striatum drug effects, Disease Models, Animal, Green Fluorescent Proteins, Nerve Degeneration chemically induced, Nerve Degeneration pathology, Nerve Degeneration physiopathology, Neurons cytology, Phenotype, Rats, Recovery of Function physiology, Regeneration physiology, Stem Cells cytology, Time Factors, Up-Regulation physiology, Brain Injury, Chronic physiopathology, Corpus Striatum physiopathology, Neurogenesis physiology, Neurons physiology, Neurotoxins toxicity, Stem Cells physiology
- Abstract
Experimental stroke and excitotoxic brain lesion to the striatum increase the proliferation of cells residing within the ventricular wall and cause subsequent migration of newborn neuroblasts into the lesioned brain parenchyma. In this study, we clarify the different events of neurogenesis following striatal or cortical excitotoxic brain lesions in adult rats. Newborn cells were labeled by intraperitoneal injection of bromo-deoxy-uridine (BrdU), or by green fluorescent protein (GFP)-expressing lentiviral vectors injected into the subventricular zone (SVZ). We show that only neural progenitors born the first 5 days in the SVZ reside and expand within this neurogenic niche over time, and that these early labeled cells are more prone to migrate towards the striatum as neuroblasts. However, these neuroblasts could not mature into NeuN+ neurons in the striatum. Furthermore, we found that cortical lesions, close or distant from the SVZ, could not upregulate SVZ cell proliferation nor promote neurogenesis. Our study demonstrates that both the time window for labeling proliferating cells and the site of lesion are crucial when assessing neurogenesis following brain injury.
- Published
- 2009
- Full Text
- View/download PDF
18. Activation of tumor cell integrin alphavbeta3 controls angiogenesis and metastatic growth in the brain.
- Author
-
Lorger M, Krueger JS, O'Neal M, Staflin K, and Felding-Habermann B
- Subjects
- Adaptor Proteins, Signal Transducing metabolism, Animals, Apoptosis, Blotting, Western, Brain Neoplasms genetics, Brain Neoplasms metabolism, Cell Cycle Proteins, Cell Line, Tumor, Cell Proliferation, Female, Gene Expression Regulation, Neoplastic, Humans, Hypoxia, In Situ Nick-End Labeling, Integrin alphaVbeta3 genetics, Mammary Neoplasms, Experimental genetics, Mammary Neoplasms, Experimental metabolism, Mice, Mice, SCID, Mutation, Neoplasm Transplantation, Phosphoproteins metabolism, Phosphorylation, Protein Processing, Post-Translational, Reverse Transcriptase Polymerase Chain Reaction, Transplantation, Heterologous, Tumor Burden, Vascular Endothelial Growth Factor A genetics, Vascular Endothelial Growth Factor A metabolism, Brain Neoplasms secondary, Integrin alphaVbeta3 metabolism, Mammary Neoplasms, Experimental pathology, Neovascularization, Pathologic pathology
- Abstract
The incidence of brain metastasis is rising and poses a severe clinical problem, as we lack effective therapies and knowledge of mechanisms that control metastatic growth in the brain. Here we demonstrate a crucial role for high-affinity tumor cell integrin alpha(v)beta(3) in brain metastatic growth and recruitment of blood vessels. Although alpha(v)beta(3) is frequently up-regulated in primary brain tumors and metastatic lesions of brain homing cancers, we show that it is the alpha(v)beta(3) activation state that is critical for brain lesion growth. Activated, but not non-activated, tumor cell alpha(v)beta(3) supports efficient brain metastatic growth through continuous up-regulation of vascular endothelial growth factor (VEGF) protein under normoxic conditions. In metastatic brain lesions carrying activated alpha(v)beta(3), VEGF expression is controlled at the post-transcriptional level and involves phosphorylation and inhibition of translational respressor 4E-binding protein (4E-BP1). In contrast, tumor cells with non-activated alpha(v)beta(3) depend on hypoxia for VEGF induction, resulting in reduced angiogenesis, tumor cell apoptosis, and inefficient intracranial growth. Importantly, the microenvironment critically influences the effects that activated tumor cell alpha(v)beta(3) exerts on tumor cell growth. Although it strongly promoted intracranial growth, the activation state of the receptor did not influence tumor growth in the mammary fat pad as a primary site. Thus, we identified a mechanism by which metastatic cells thrive in the brain microenvironment and use the high-affinity form of an adhesion receptor to grow and secure host support for proliferation. Targeting this molecular mechanism could prove valuable for the inhibition of brain metastasis.
- Published
- 2009
- Full Text
- View/download PDF
19. Identification of proteins involved in neural progenitor cell targeting of gliomas.
- Author
-
Staflin K, Zuchner T, Honeth G, Darabi A, and Lundberg C
- Subjects
- Animals, Antineoplastic Agents therapeutic use, Cell Line, Tumor, Disease Models, Animal, Disease Progression, Immunohistochemistry methods, Oligonucleotide Array Sequence Analysis, Rats, Reverse Transcriptase Polymerase Chain Reaction, Time Factors, Treatment Outcome, Tumor Protein, Translationally-Controlled 1, Brain Neoplasms metabolism, Brain Neoplasms therapy, Glioma metabolism, Glioma therapy, Neurons cytology, Stem Cells cytology
- Abstract
Background: Glioblastoma are highly aggressive tumors with an average survival time of 12 months with currently available treatment. We have previously shown that specific embryonic neural progenitor cells (NPC) have the potential to target glioma growth in the CNS of rats. The neural progenitor cell treatment can cure approximately 40% of the animals with malignant gliomas with no trace of a tumor burden 6 months after finishing the experiment. Furthermore, the NPCs have been shown to respond to signals from the tumor environment resulting in specific migration towards the tumor. Based on these results we wanted to investigate what factors could influence the growth and progression of gliomas in our rodent model., Methods: Using microarrays we screened for candidate genes involved in the functional mechanism of tumor inhibition by comparing glioma cell lines to neural progenitor cells with or without anti-tumor activity. The expression of candidate genes was confirmed at RNA level by quantitative RT-PCR and at the protein level by Western blots and immunocytochemistry. Moreover, we have developed in vitro assays to mimic the antitumor effect seen in vivo., Results: We identified several targets involved in glioma growth and migration, specifically CXCL1, CD81, TPT1, Gas6 and AXL proteins. We further showed that follistatin secretion from the NPC has the potential to decrease tumor proliferation. In vitro co-cultures of NPC and tumor cells resulted in the inhibition of tumor growth. The addition of antibodies against proteins selected by gene and protein expression analysis either increased or decreased the proliferation rate of the glioma cell lines in vitro., Conclusion: These results suggest that these identified factors might be useful starting points for performing future experiments directed towards a potential therapy against malignant gliomas.
- Published
- 2009
- Full Text
- View/download PDF
20. Instructive cross-talk between neural progenitor cells and gliomas.
- Author
-
Staflin K, Lindvall M, Zuchner T, and Lundberg C
- Subjects
- Animals, Brain Neoplasms pathology, Brain Neoplasms physiopathology, Cell Line, Tumor, Cell Movement, Cell Survival, Corpus Striatum, Glioma pathology, Glioma physiopathology, Phenotype, Rats, Stem Cells metabolism, Vimentin metabolism, Brain Neoplasms surgery, Cell Communication, Glioma surgery, Neurons cytology, Stem Cell Transplantation, Stem Cells cytology, Stem Cells physiology
- Abstract
Gliomas are the most common primary brain tumors and offer a poor prognosis in patients because of their infiltrative and treatment-resistant nature. The median survival time after diagnosis is approximately 11-12 months. There is a strong need for novel treatment modalities in targeting gliomas, and recent advances use neural progenitor cells as delivery systems for different therapeutic strategies. In this study, we show that rat embryonic neural progenitor cell (NPC) lines, transplanted at a distant site from a 3-day-preestablished glioma in the striatum, were able to migrate toward and colocalize with tumor isles without general spread into the brain parenchyma. Upon encounter with tumor, neural progenitor cells changed phenotype and became vimentin positive. These results demonstrate that transplanted neural progenitor cells respond to queues from a tumor and home to and exert an antitumor effect on the preestablished glioma, significantly decreasing the tumor volume with approximately 67% compared with control tumors after 1-2 weeks. Moreover, these early effects could be translated into increased survival times of animals treated with neural progenitor cell grafts 3 days after intrastriatal tumor inoculation. In contrast, there was no activation or migration of endogenous subventricular zone (SVZ) neuroblasts in response to an intrastriatal syngeneic tumor. In conclusion, NPC possess the ability to influence tumor growth as well as respond to queues from the tumor or tumor microenvironment, demonstrating a cross-talk between the cells., ((c) 2007 Wiley-Liss, Inc.)
- Published
- 2007
- Full Text
- View/download PDF
21. Neural progenitor cell lines inhibit rat tumor growth in vivo.
- Author
-
Staflin K, Honeth G, Kalliomäki S, Kjellman C, Edvardsen K, and Lindvall M
- Subjects
- Animals, Brain Neoplasms immunology, Brain Neoplasms pathology, Colonic Neoplasms immunology, Colonic Neoplasms pathology, Corpus Striatum pathology, Glioma immunology, Glioma pathology, Hippocampus pathology, Humans, Immunosuppressive Agents metabolism, Male, Neurons cytology, Neurons transplantation, Rats, Rats, Inbred F344, Rats, Sprague-Dawley, Stem Cells cytology, Survival Rate, Transforming Growth Factor beta metabolism, Tumor Cells, Cultured, Brain Neoplasms prevention & control, Colonic Neoplasms prevention & control, Glioma prevention & control, Neurons physiology, Stem Cells physiology
- Abstract
Current therapies for gliomas often fail to address their infiltrative nature. Conventional treatments leave behind small clusters of neoplastic cells, resulting in eventual tumor recurrence. In the present study, we have evaluated the antitumor activity of neural progenitor cells against gliomas when stereotactically injected into nucleus Caudatus of Fisher rats. We show that the rat neural progenitor cell lines HiB5 and ST14A, from embryonic hippocampus and striatum primordium, respectively, are able to prolong animal survival and, in 25% of the cases, completely inhibit the outgrowth of N29 glioma compared with control animals. Delayed tumor outgrowth was also seen when HiB5 cells were inoculated at the site of tumor growth 1 week after tumor inoculation or when a mixture of tumor cells and HiB5 cells were injected s.c. into Fisher rats. HiB5 cells were additionally coinoculated together with two alternative rat gliomas, N32 and N25. N32 was growth inhibited, but rats inoculated with N25 cells did not show a prolonged survival. To evaluate the possibility of the involvement of the immune system in the tumor outgrowth inhibition, we show that HiB5 cells do not evoke an immune response when injected into Fisher rats. Furthermore, the rat neural progenitor cells produce all transforming growth factor beta isotypes, which could explain the observed immunosuppressive nature of these cells. Hence, some neural progenitor cells have the ability to inhibit tumor outgrowth when implanted into rats. These results indicate the usefulness of neural stem cells as therapeutically effective cells for the treatment of intracranial tumors.
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.